Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume -, Issue -, Pages annrheumdis-2022-222259
Publisher
BMJ
Online
2022-09-23
DOI
10.1136/ard-2022-222259
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
- (2022) Farzin Khosrow-Khavar et al. ANNALS OF THE RHEUMATIC DISEASES
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
- (2022) Andra-Rodica Balanescu et al. ANNALS OF THE RHEUMATIC DISEASES
- Cardiovascular effects of approved drugs for rheumatoid arthritis
- (2021) Fabiola Atzeni et al. Nature Reviews Rheumatology
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
- (2021) Frank L J Visseren et al. EUROPEAN HEART JOURNAL
- Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
- (2021) Peter C Taylor et al. ANNALS OF THE RHEUMATIC DISEASES
- Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
- (2020) Philip Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
- (2020) Darren K. McGuire et al. JAMA Cardiology
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
- (2019) Scott M. Grundy et al. CIRCULATION
- Comparative Risk of Cardiovascular Events with Biologic and Synthetic Disease‐Modifying Anti‐Rheumatic Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta‐analysis
- (2019) Siddharth Singh et al. ARTHRITIS CARE & RESEARCH
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
- (2019) Donna K. Arnett et al. CIRCULATION
- Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis
- (2019) Christina Charles‐Schoeman et al. Arthritis & Rheumatology
- Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial
- (2019) Jon T. Giles et al. Arthritis & Rheumatology
- Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis
- (2018) Daniel H. Solomon et al. Arthritis & Rheumatology
- EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
- (2016) R Agca et al. ANNALS OF THE RHEUMATIC DISEASES
- Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
- (2016) Steven E. Nissen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
- (2015) Christina Charles-Schoeman et al. Arthritis & Rheumatology
- The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis
- (2014) Jie Zhang et al. ANNALS OF THE RHEUMATIC DISEASES
- Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment
- (2014) E. Choy et al. RHEUMATOLOGY
- 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
- (2013) David C. Goff et al. CIRCULATION
- Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies
- (2012) Juan Antonio Avina-Zubieta et al. ANNALS OF THE RHEUMATIC DISEASES
- Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
- (2010) G. D. Kitas et al. ANNALS OF THE RHEUMATIC DISEASES
- A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group
- (2010) Jeff J. Guo et al. VALUE IN HEALTH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now